Jaguar Health Advances Crofelemer for Pediatric MVID
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: Newsfilter
Jaguar Health Inc. has seen its stock price drop by 11.63%, hitting a 52-week low amid broader market gains, with the Nasdaq-100 up 1.18% and the S&P 500 up 0.73%.
The company has engaged with the FDA to explore Breakthrough Therapy Designation for Crofelemer as a treatment for pediatric patients with microvillus inclusion disease (MVID). Preliminary clinical results indicate significant improvements in patient outcomes, including weight and height gains, as well as reduced parenteral support needs. This advancement highlights the potential of Crofelemer in addressing a critical unmet medical need.
The implications of this development could be substantial for Jaguar Health, as successful FDA designation may enhance investor confidence and market positioning, despite the current stock price volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAGX
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jaguar Health Reports Q1 Earnings Results
- Earnings Performance: Jaguar Health reported a Q1 GAAP EPS of -$13.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Surge: The company achieved revenue of $20.27 million in Q1, a substantial increase from $2.21 million in Q1 2025, reflecting a notable rise in market demand for its products or services.
- Market Reaction: Despite the impressive revenue growth, the ongoing losses may raise concerns about the company's future financial health, potentially impacting stock performance.
- Need for Strategic Adjustment: In light of the substantial losses, Jaguar Health may need to reassess its business model and cost structure to achieve sustainable profitability and enhance its competitive position in the market.
See More
Jaguar Health Reports 816% Revenue Surge in Q1 2026
- Revenue Surge: Jaguar Health's net revenue for Q1 2026 skyrocketed by 816% year-over-year and 527% quarter-over-quarter, primarily driven by a $16 million initial payment from Future Pak under a licensing agreement, significantly enhancing the company's financial outlook.
- Sales Shift: Prescription product revenue totaled $1.2 million, reflecting a 45% decline from Q1 2025, indicating a strategic shift as U.S. product revenues transitioned to Future Pak, highlighting a major adjustment in the company's market strategy.
- R&D Advancements: Jaguar is advancing crofelemer for rare disease intestinal failure indications, with two presentations scheduled at the ESPGHAN Annual Meeting in June 2026 on microvillus inclusion disease and short bowel syndrome, demonstrating the company's ongoing commitment to research and development.
- Upcoming Events: The company will host an investor webcast on May 26, 2026, to discuss Q1 results and updates, while CEO Lisa Conte is set to present at the Lytham Partners Spring 2026 Investor Conference on May 28, enhancing investor communication and engagement.
See More
Jaguar (JAGX) Q4 2025 Earnings Transcript
See More
Jaguar Health Announces Investor Webcast and Conference Presentation Dates
- Earnings Report Filing: Jaguar Health plans to file its Form 10-Q on May 20, 2026, for the quarter ended March 31, 2026, aiming to provide investors with an update on its financial status and business developments.
- Investor Webcast: The company will hold an investor webcast on May 26, 2026, at 8:30 a.m. Eastern, where founder and CEO Lisa Conte will review first-quarter financials and provide corporate updates.
- Lytham Partners Conference: Jaguar will also present at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026, at 10 a.m. Eastern, further showcasing its strategic direction and market potential.
- Replay Availability: Replays of all webcasts and presentations will be available in the investor relations section of Jaguar's website, ensuring that investors who cannot attend live can access key information.
See More
Jaguar Health Advances Crofelemer Development for Pediatric MVID
- Breakthrough Therapy Designation: Jaguar Health has engaged with the FDA to explore the possibility of Breakthrough Therapy Designation for oral Crofelemer as an adjunctive treatment for pediatric patients with microvillus inclusion disease (MVID), addressing a critical unmet need with no current therapies available.
- Preliminary Clinical Results: Crofelemer has shown significant reductions in weekly parenteral support (PS) needs in two pediatric MVID patients during two open-label studies, with initial results set to be presented at the 2026 ESPGHAN meeting, indicating promising clinical application potential.
- Patient Improvement: Pediatric MVID patients receiving Crofelemer have demonstrated weight and height gains, alongside reductions in daily and weekly PS requirements, which are expected to enhance clinical outcomes and quality of life while alleviating severe comorbidities associated with PS.
- Regulatory Pathway Exploration: Jaguar and its subsidiary Napo Pharmaceuticals have received orphan drug designations for both MVID and short bowel syndrome, continuing to advance Crofelemer's development with the aim of submitting to the FDA as soon as clinical and regulatory activities are completed.
See More
Geely's Strategic Positioning in the U.S. Market
- Market Access Advantage: Despite the U.S. imposing a 100% tariff on Chinese EVs, Geely has established a robust dealer network through its brands like Volvo, Polestar, and Lotus, enhancing its market access capabilities and demonstrating strategic positioning in the U.S. market.
- Production Capacity Potential: The Volvo factory in South Carolina has a production capacity of 150,000 vehicles annually but only produced about 18,500 in 2025; plans to increase production of the XC60 hybrid SUV could add approximately 45,000 units, further enhancing Geely's production capabilities.
- Brand Expansion Plans: Geely's Zeekr brand is seen as the most likely candidate for U.S. market entry, with Waymo already utilizing Zeekr vehicles for its self-driving fleet in San Francisco, showcasing its potential in technology and market adaptability.
- Policy Environment Impact: Despite bipartisan opposition, President Trump has expressed openness to Chinese automakers building plants in the U.S., potentially providing new market opportunities for Geely and other Chinese automotive brands, further driving their expansion plans in the U.S.
See More
Jaguar Health Reports Q1 Earnings Results
- Earnings Performance: Jaguar Health reported a Q1 GAAP EPS of -$13.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Surge: The company achieved revenue of $20.27 million in Q1, a substantial increase from $2.21 million in Q1 2025, reflecting a notable rise in market demand for its products or services.
- Market Reaction: Despite the impressive revenue growth, the ongoing losses may raise concerns about the company's future financial health, potentially impacting stock performance.
- Need for Strategic Adjustment: In light of the substantial losses, Jaguar Health may need to reassess its business model and cost structure to achieve sustainable profitability and enhance its competitive position in the market.
See More
Jaguar Health Reports 816% Revenue Surge in Q1 2026
- Revenue Surge: Jaguar Health's net revenue for Q1 2026 skyrocketed by 816% year-over-year and 527% quarter-over-quarter, primarily driven by a $16 million initial payment from Future Pak under a licensing agreement, significantly enhancing the company's financial outlook.
- Sales Shift: Prescription product revenue totaled $1.2 million, reflecting a 45% decline from Q1 2025, indicating a strategic shift as U.S. product revenues transitioned to Future Pak, highlighting a major adjustment in the company's market strategy.
- R&D Advancements: Jaguar is advancing crofelemer for rare disease intestinal failure indications, with two presentations scheduled at the ESPGHAN Annual Meeting in June 2026 on microvillus inclusion disease and short bowel syndrome, demonstrating the company's ongoing commitment to research and development.
- Upcoming Events: The company will host an investor webcast on May 26, 2026, to discuss Q1 results and updates, while CEO Lisa Conte is set to present at the Lytham Partners Spring 2026 Investor Conference on May 28, enhancing investor communication and engagement.
See More
Jaguar (JAGX) Q4 2025 Earnings Transcript
See More
Jaguar Health Announces Investor Webcast and Conference Presentation Dates
- Earnings Report Filing: Jaguar Health plans to file its Form 10-Q on May 20, 2026, for the quarter ended March 31, 2026, aiming to provide investors with an update on its financial status and business developments.
- Investor Webcast: The company will hold an investor webcast on May 26, 2026, at 8:30 a.m. Eastern, where founder and CEO Lisa Conte will review first-quarter financials and provide corporate updates.
- Lytham Partners Conference: Jaguar will also present at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026, at 10 a.m. Eastern, further showcasing its strategic direction and market potential.
- Replay Availability: Replays of all webcasts and presentations will be available in the investor relations section of Jaguar's website, ensuring that investors who cannot attend live can access key information.
See More
Jaguar Health Advances Crofelemer Development for Pediatric MVID
- Breakthrough Therapy Designation: Jaguar Health has engaged with the FDA to explore the possibility of Breakthrough Therapy Designation for oral Crofelemer as an adjunctive treatment for pediatric patients with microvillus inclusion disease (MVID), addressing a critical unmet need with no current therapies available.
- Preliminary Clinical Results: Crofelemer has shown significant reductions in weekly parenteral support (PS) needs in two pediatric MVID patients during two open-label studies, with initial results set to be presented at the 2026 ESPGHAN meeting, indicating promising clinical application potential.
- Patient Improvement: Pediatric MVID patients receiving Crofelemer have demonstrated weight and height gains, alongside reductions in daily and weekly PS requirements, which are expected to enhance clinical outcomes and quality of life while alleviating severe comorbidities associated with PS.
- Regulatory Pathway Exploration: Jaguar and its subsidiary Napo Pharmaceuticals have received orphan drug designations for both MVID and short bowel syndrome, continuing to advance Crofelemer's development with the aim of submitting to the FDA as soon as clinical and regulatory activities are completed.
See More
Geely's Strategic Positioning in the U.S. Market
- Market Access Advantage: Despite the U.S. imposing a 100% tariff on Chinese EVs, Geely has established a robust dealer network through its brands like Volvo, Polestar, and Lotus, enhancing its market access capabilities and demonstrating strategic positioning in the U.S. market.
- Production Capacity Potential: The Volvo factory in South Carolina has a production capacity of 150,000 vehicles annually but only produced about 18,500 in 2025; plans to increase production of the XC60 hybrid SUV could add approximately 45,000 units, further enhancing Geely's production capabilities.
- Brand Expansion Plans: Geely's Zeekr brand is seen as the most likely candidate for U.S. market entry, with Waymo already utilizing Zeekr vehicles for its self-driving fleet in San Francisco, showcasing its potential in technology and market adaptability.
- Policy Environment Impact: Despite bipartisan opposition, President Trump has expressed openness to Chinese automakers building plants in the U.S., potentially providing new market opportunities for Geely and other Chinese automotive brands, further driving their expansion plans in the U.S.
See More
